StemCell Therapy

Analysts expect that Unity Biotechnology Inc (NASDAQ:UBX) will report earnings of ($0.49) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Unity Biotechnologys earnings. Unity Biotechnology posted earnings of ($0.43) per share in the same quarter last year, which indicates a negative year over year growth rate of 14%. The firm is expected to announce its next earnings report after the market closes on Wednesday, November 6th.

On average, analysts expect that Unity Biotechnology will report full year earnings of ($2.02) per share for the current financial year, with EPS estimates ranging from ($2.07) to ($1.96). For the next year, analysts expect that the company will post earnings of ($2.09) per share, with EPS estimates ranging from ($2.25) to ($1.93). Zacks Investment Researchs earnings per share averages are an average based on a survey of research firms that follow Unity Biotechnology.

Unity Biotechnology (NASDAQ:UBX) last released its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts consensus estimates of ($0.44) by ($0.10).

Institutional investors and hedge funds have recently made changes to their positions in the company. Aperio Group LLC acquired a new position in shares of Unity Biotechnology during the 2nd quarter worth $50,000. Citadel Advisors LLC grew its stake in Unity Biotechnology by 449.0% in the 2nd quarter. Citadel Advisors LLC now owns 238,386 shares of the companys stock valued at $2,265,000 after buying an additional 194,965 shares during the last quarter. Ellington Management Group LLC acquired a new position in Unity Biotechnology in the 2nd quarter valued at $103,000. BlackRock Inc. grew its stake in Unity Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,992,613 shares of the companys stock valued at $18,929,000 after buying an additional 94,183 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in Unity Biotechnology by 84.8% in the 2nd quarter. Virtus ETF Advisers LLC now owns 30,554 shares of the companys stock valued at $290,000 after buying an additional 14,021 shares during the last quarter. Institutional investors own 38.32% of the companys stock.

UBX stock opened at $6.88 on Friday. Unity Biotechnology has a 12-month low of $5.61 and a 12-month high of $17.46. The company has a market cap of $295.51 million, a price-to-earnings ratio of -2.71 and a beta of -0.19. The company has a 50 day moving average of $6.81 and a two-hundred day moving average of $7.63.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders.

Read More: Dollar Cost Averaging

Get a free copy of the Zacks research report on Unity Biotechnology (UBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read more from the original source:
Brokerages Anticipate Unity Biotechnology Inc (NASDAQ:UBX) Will Announce Earnings of -$0.49 Per Share - Slater Sentinel

This entry was posted on November 10, 2019 at 5:42 am and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |